Updates in Advanced Renal Cell Carcinoma from The 2022 International Kidney Cancer Symposium : Episode 2
Comparing IO/IO and IO/TKI Frontline Treatment in Advanced RCC
Moshe Ornstein, MD, MA, explains his reasoning for starting patients with advanced renal cell carcinoma on an IO/IO combination regimen.
EP: 1.Overview of the Frontline Management and Risk Stratification of Advanced Renal Cell Carcinoma (RCC)
Now Viewing
EP: 2.Comparing IO/IO and IO/TKI Frontline Treatment in Advanced RCC
EP: 3.Updates from the CLEAR Study on Efficacy of Lenvatinib plus Pembrolizumab in Patients with Advanced RCC
EP: 4.Lenvatinib Dosing Strategies in Frontline Advanced RCC Treatment
EP: 5.Nivolumab plus Ipilimumab for Frontline Treatment of Advanced RCC: 5-Year Follow-Up from the CheckMate 214 Trial
EP: 6.Managing Adverse Events of IO/IO Frontline Combination Therapies in Advanced RCC Treatment
EP: 7.COSMIC-313: Frontline Triplet Therapy in Advanced RCC
EP: 8.Emerging Data in Non-Clear Cell RCC Treatment
EP: 9.Exciting Investigational Therapies in Advanced RCC
Related Videos
Related Content
